Aldosterone News and Research

RSS

Aldosterone is a steroid hormone made by the adrenal cortex (the outer layer of the adrenal gland). It helps control the balance of water and salts in the kidney by keeping sodium in and releasing potassium from the body. Too much aldosterone can cause high blood pressure and a build-up of fluid in body tissues. Aldosterone is a type of mineralocorticoid hormone.

Trial finds no cardiovascular benefit and higher safety risks with spironolactone in dialysis patients

A large international study has found that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalizations in people with kidney failure receiving dialysis, despite earlier smaller studies suggesting benefit.

17 Aug 2025

New 2025 guidelines focus on early intervention and lifestyle to manage high blood pressure

Preventing and managing high blood pressure with healthy lifestyle behaviors, such as following a heart-healthy diet including reducing salt intake, staying physically active, maintaining a healthy weight and managing stress—combined with early treatment with medication to lower blood pressure if necessary—are recommended to reduce the risk of heart attack, stroke, heart failure, kidney disease, cognitive decline and dementia, according to a new clinical guideline published today in the American Heart Association's peer-reviewed journals Circulation and Hypertension, and in JACC, the flagship journal of the American College of Cardiology.

14 Aug 2025

Endocrine Society experts call for more widespread screening of primary aldosteronism

Endocrine Society experts encouraged more widespread screening for a common hormonal cause of high blood pressure known as primary aldosteronism in a new Clinical Practice Guideline released today.

14 Jul 2025

Premenstrual symptoms linked to higher risk of cardiovascular disease

Women diagnosed with premenstrual symptoms have a slightly increased risk of developing cardiovascular disease later in life.

11 Jul 2025

Aldosterone synthase inhibitor offers hope for treatment of uncontrolled hypertension

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with uncontrolled or resistant hypertension, according to the results of a phase 3 trial announced today.

24 May 2025

Guideline-directed medical therapy boosts survival in the oldest heart attack patients

Researchers have found that prescribing guideline-directed medical treatment (GDMT), regardless of the number of medications, can improve survival rates in patients 90 years of age and older following their first heart attack, with the greatest benefit observed in patients who received all four recommended post-acute myocardial infarction (AMI) therapies.

22 May 2025

Investigational drug lorundrostat offers significant blood pressure drop compared with placebo

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

How gut health shapes heart disease risk — and what you can do about it

A new review highlights how gut microbiome imbalances contribute to cardiovascular disease by altering short-chain fatty acids, TMAO, and inflammatory pathways. The study emphasizes the potential of prebiotics, probiotics, and dietary changes to restore gut health and reduce heart disease risk.

13 Mar 2025

UCL researchers develop groundbreaking therapy for a common cause of high blood pressure

A minimally invasive therapy that has the potential to transform treatment of a common cause of high blood pressure, has been developed by researchers at UCL, Queen Mary University of London and Barts Health.

25 Feb 2025

Researchers uncover a surprising layer of complexity in aldosterone-producing tumors

Kyushu University researchers have uncovered a surprising layer of complexity in aldosterone-producing adenomas (APAs)-adrenal gland tumors that drive high blood pressure.

24 Feb 2025

A step toward precision medicine: New drug targets for heart failure

Researchers identify several promising drug targets for heart failure and its clinical subtypes.

14 Feb 2025

New minimally invasive treatment offers hope for primary aldosteronism

Doctors at Queen Mary University of London, Barts Health NHS Trust, and University College London have led the development of a simple, minimally invasive Targeted Thermal Therapy (Triple T) that has the potential to transform medical management of a common, but commonly overlooked, cause of high blood pressure.

10 Feb 2025

Targeted Thermal Therapy could transform management of common cause of high blood pressure

8 Feb 2025

Study reveals pathways behind organ damage in severe COVID-19

New research published in the journal Proceedings of the National Academy of Sciences sheds light on the pathways that drive organ damage and death in severe COVID-19 and helps explain why survivors of the disease can experience long-term complications.

2 Dec 2024

Researchers discover new cause of cytokine storm in COVID-19

As part of the COVID-19 International Research Team, researchers at the Johns Hopkins Kimmel Cancer Center, Children's Hospital of Philadelphia, the University of Pittsburgh and Weill Cornell Medicine discovered a novel cause of cytokine storm - the extreme inflammatory response associated with increased risk of death in COVID-19 infection.

2 Dec 2024

Understanding the pathophysiological relationship between OSA and metabolic syndrome

Cardiovascular diseases remain a leading cause of mortality globally, particularly among individuals with both obstructive sleep apnea (OSA) and metabolic syndrome (MetS).

27 Nov 2024

NIH awards grant to study how dilated cardiomyopathy progresses to heart failure

A University of Arizona College of Medicine – Phoenix researcher was recently awarded a $1.9 million National Institutes of Health grant to study the molecular mechanisms of how dilated cardiomyopathy progresses to heart failure, which could eventually lead to better preventive and treatment options for heart failure.

27 Sep 2024